Soluble mesothelin-related peptides (SMRP) - High stability of a potential tumor marker for mesothelioma

Cancer Biomarkers

Volumn 3, Issue 6, 2007, Pages 287-292

  Weber, Daniel G ^a   Taeger, Dirk ^a   Pesch, Beate ^a   Kraus, Thomas ^b   Brüning, Thomas ^a   Johnen, Georg ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Marker; Mesothelin; Mesothelioma; Serum; SMRP

Indexed keywords

ANTIGEN; MESOTHELIN; SOLUBLE MESOTHELIN RELATED PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; CANCER DIAGNOSIS; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIELD STUDY; FOLLOW UP; FREEZE THAWING; HUMAN; MALE; MALIGNANT MESOTHELIOMA; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN STABILITY; STORAGE TEMPERATURE; VALIDATION PROCESS;

EID: 36549088670     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2007-3602     Document Type: Article

References (19)

1. B.W. Robinson, J. Creaney, R. Lake, A. Nowak, A.W. Musk, N. De Klerk, P. Winzell, K.E. Hellstrom and I. Hellstrom, Soluble mesothelin-related protein-a blood test for mesothelioma, Lung Cancer 49 (2005), S109-S111.
2. K. Chang and I. Pastan, Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers, Proc Natl Acad Sci USA 93 (1996), 136-140.
3. K. Chang, L.H. Pai, H. Pass, H.W. Pogrebniak, M.S. Tsao, I. Pastan and M.C. Willingham, Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma, Am J Surg Pathol 16 (1992), 259-268.
4. I. Hellstrom, J. Raycraft, S. Kanan, N.Y. Sardesai, T. Verch, Y. Yang and K.E. Hellstrom, Mesothelin variant 1 is released from tumor cells as a diagnostic marker, Cancer Epidemiol Biomarkers Prev 15 (2006), 1014-1020.
5. M. Ho, M. Onda, Q.C. Wang, R. Hassan, I. Pastan and M.O. Lively, Mesothelin is shed from tumor cells, Cancer Epidemiol Biomarkers Prev 15 (2006), 1751.
6. R. Hassan, T. Bera and I. Pastan, Mesothelin: A new target for immunotherapy, Clin Cancer Res 10 (2004), 3937-3942.
7. A. Scherpereel, B.D. Grigoriu, M. Conti, T. Gey, M. Gregoire, M.C. Copin, P. Devos, B. Chahine, H. Porte and P. Lassalle, Soluble Mesothelin-related Protein in the Diagnosis of Malignant Pleural Mesothelioma, Am J Respir Crit Care Med 173 (2006), 1155-1160.
8. B.W. Robinson, J. Creaney, R. Lake, A. Nowak, A.W. Musk, N. De Klerk, P. Winzell, K.E. Hellstrom and I. Hellstrom, Mesothelin-family proteins and diagnosis of mesothelioma, Lancet 362 (2003), 1612-1616.
9. H.I. Pass, D. Wolaniuk, A. Wali, R. Thiel, I. Hellstrom, K. Hellstrom and N.Y. Sardesai, Soluble Mesothelin Related Peptides: A Potential Biomarker for Malignant Pleural Mesothelioma, J Clin Oncol (Meeting Abstracts) 23 (2005), 9532.
10. C.G. Fraser, Inherent biological variation and reference values, Clin Chem Lab Med 42 (2004), 758-764.
11. N. Scholler, N. Fu, Y. Yang, Z. Ye, G.E. Goodman, K.E. Hellstrom and I. Hellstrom, Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma, Proc Natl Acad Sci USA 96 (1999), 11531-11536.
12. E. Limpert, W. Stahl and M. Abbt, Lognormal distributions across the sciences: Keys and clues, Bioscience 51 (2001), 341-352.
13. J.M. Bland and D.G. Altman, Measuring agreement in method comparison studies, Stat Methods Med Res 8 (1999), 135-160.
14. M.W. McIntosh, C. Drescher, B. Karlan, N. Scholler, N. Urban, K.E. Hellstrom and I. Hellstrom, Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma, Gynecol Oncol 95 (2004), 9-15.
15. H.L. Beyer, R.D. Geschwindt, C.L. Glover, L. Tran, I. Hellstrom, K.E. Hellstrom, M.C. Miller, T. Verch, W.J. Allard, H.I. Pass and N.Y. Sardesai, MESOMARK: A potential test for malignant pleural mesothelioma, Clin Chem 53 (2007), 666-672.
16. J. Creaney, H. Christansen, R. Lake, A.W. Musk, N. De Klerk and B.W. Robinson, Soluble Mesothelin related Protein in Mesothelioma, Journal of Thoracic Oncology 1 (2006), 172-174.
17. G. Hillerdal, U. Lindqvist and A. Engstrom-Laurent, Hyaluronan in pleural effusions and in serum, Cancer 67 (1991), 2410-2414.
18. H.I. Pass, D. Lott, F. Lonardo, M. Harbut, Z. Liu, N. Tang, M. Carbone, C. Webb and A. Wali, Asbestos exposure, pleural mesothelioma, and serum osteopontin levels, N Engl J Med 353 (2005), 1564-1573.
19. M. Hedman, H. Arnberg, J. Wernlund, H. Riska and O. Brodin, Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma, Anticancer Res 23 (2003), 531-536.